The FDA has issued a warning that popular nerve drugs may carry a risk of serious, potentially deadly breathing problems.
"With the evolution of the opioid crisis, getting ahead of new concerns or addressing those that are already evident requires examining signs of misuse and abuse as soon as any signal emerges," said Dr. Douglas Throckmorton, deputy director for Regulatory Programs in the FDA's Center for Drug Evaluation and Research.
"Reports of gabapentinoid abuse alone, and with opioids, have emerged and there are serious consequences of this co-use, including respiratoryAlong with the new warnings about potential breathing dangers, the FDA ordered drugmakers to conduct clinical trials to further evaluate the abuse risk of gabapentinoids, particularly in combination with opioids, with special emphasis on assessing the breathing dangers.
Between 2012 and 2016, the number of patients who filled a gabapentin prescription increased from 8.3 million to 13.1 million a year, and the number of patients who filled a pregabalin prescription increased from 1.9 million to 2.1 million a year, according to the FDA. In addition, 2016 data show that 14% to 19% of patient encounters with doctors that involved gabapentin and pregabalin, respectively, also involved opioids.Copyright © 2013-2018 HealthDay. All rights reserved.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
For the first time, FDA approves vaccine to prevent deadly Ebola virusSince last year, more than 2,200 people have died in the Democratic Republic of the Congo in the world's second largest outbreak of the virus ever.
Consulte Mais informação »
Merck receives FDA approval for Ebola vaccineThe U.S. Food and Drug Administration said on Thursday it granted approval to dr...
Consulte Mais informação »
Special Report: FDA targets e-cigs that hook teens but don't help smokers quitBy May, they must submit applications to the U.S. Food and Drug Administration proving that their products provide a net benefit to public health. If a company fails to make its case, the FDA has the power to order its products off the market. The data show that e-cigarettes are having little impact
Consulte Mais informação »
FDA targets e-cigs that hook teens but don't help smokers quitBy May, e-cigarette makers must submit applications to the FDA proving that their products provide a net benefit to public health.
Consulte Mais informação »
FDA approves first Ebola vaccine in the U.S.An earlier study found the vaccine to be 100 percent effective in preventing Ebola.
Consulte Mais informação »